文献速递儿科与产科急症

加利福尼亚州妊娠期感染与未感染SARS-CoV-2者的围产期并发症

Perinatal Complications in Individuals in California With or Without SARS-CoV-2 Infection During Pregnancy.
PubMed 文献 · JAMA Intern Med · 2022-01-01
一句话结论妊娠期SARS-CoV-2感染与严重孕产妇发病率、早产和静脉血栓栓塞风险升高相关,支持为孕妇和计划妊娠者接种疫苗。

这项基于人群的队列研究纳入2020年3月1日至2021年3月16日在Kaiser Permanente Northern California分娩的43886名妊娠个体,其中1332名(3.0%)在从受孕前30天至分娩后7天经PCR检测发现SARS-CoV-2感染。调整人口学特征、合并症和吸烟状态后,感染组严重孕产妇发病率(HR 2.45;95%CI 1.91-3.13)、早产<37周(HR 2.08;95%CI 1.75-2.47)和静脉血栓栓塞(HR 3.08;95%CI 1.09-8.74)风险均高于未感染组。感染组中76名(5.7%)住院,孕前糖尿病(HR 7.03;95%CI 2.22-22.2)及亚洲或太平洋岛民(HR 2.33;95%CI 1.06-5.11)和黑人(HR 3.14;95%CI 1.24-7.93)种族/族裔与住院风险升高相关。作者认为研究结果支持为孕妇和计划妊娠者接种疫苗。

要点

  • 妊娠期SARS-CoV-2感染与严重孕产妇发病率风险升高相关(HR 2.45;95%CI 1.91-3.13)。
  • 妊娠期SARS-CoV-2感染与早产<37周风险升高相关(HR 2.08;95%CI 1.75-2.47)。
  • 妊娠期SARS-CoV-2感染与静脉血栓栓塞风险升高相关(HR 3.08;95%CI 1.09-8.74)。
  • 感染组中5.7%(76/1332)住院,孕前糖尿病与住院风险升高相关(HR 7.03;95%CI 2.22-22.2)。
  • 作者认为研究结果支持为孕妇和计划妊娠者接种疫苗。

适用人群与场景

  • 2020年3月1日至2021年3月16日在Kaiser Permanente Northern California分娩的43886名妊娠个体,具有从受孕前至分娩的纵向电子健康记录数据。
  • 排除标准:有COVID-19诊断编码但无SARS-CoV-2 PCR确认检测的个体。

诊断标准与关键阈值

  • SARS-CoV-2感染定义为从受孕前30天至分娩后7天经PCR检测发现感染,作为时变暴露。

研究设计与关键结果

  • 研究类型:基于人群的队列研究;样本量43886名妊娠个体(平均[SD]年龄30.7[5.2]岁),其中SARS-CoV-2感染1332名(3.0%)。
  • 感染组更可能为较年轻、西班牙裔、多产、邻里剥夺指数较高以及肥胖或慢性高血压的个体。
  • 调整人口学特征、合并症和吸烟状态后,感染组 vs 未感染组的严重孕产妇发病率(包括21种情况,如急性心肌梗死、急性肾衰竭、急性呼吸窘迫综合征和脓毒症)风险:HR 2.45(95%CI 1.91-3.13)。
  • 早产<37周风险:感染组 vs 未感染组 HR 2.08(95%CI 1.75-2.47)。
  • 静脉血栓栓塞风险:感染组 vs 未感染组 HR 3.08(95%CI 1.09-8.74)。
  • 医学指征早产风险:感染组 vs 未感染组 HR 2.56(95%CI 2.06-3.19);自然早产风险:HR 1.61(95%CI 1.22-2.13)。
  • 早期早产风险:感染组 vs 未感染组 HR 2.52(95%CI 1.49-4.24);中期早产风险:HR 2.18(95%CI 1.25-3.80);晚期早产风险:HR 1.95(95%CI 1.61-2.37)。
  • 感染组中76名(5.7%)住院;孕前糖尿病与住院风险升高相关(HR 7.03;95%CI 2.22-22.2);亚洲或太平洋岛民种族/族裔(HR 2.33;95%CI 1.06-5.11)和黑人种族/族裔(HR 3.14;95%CI 1.24-7.93)与住院风险升高相关。

证据类型、等级与局限

  • 证据类型:基于人群的队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为研究结果向临床医生和患者提供了妊娠期SARS-CoV-2感染相关围产期并发症风险的信息,并支持为孕妇和计划妊娠者接种疫苗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Additional research from population-based studies is needed to inform the treatment of SARS-CoV-2 infection during pregnancy and to provide health risk information to pregnant individuals.

OBJECTIVE: To assess the risk of perinatal complications associated with SARS-CoV-2 infection and to describe factors associated with hospitalizations.

DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study included 43 886 pregnant individuals with longitudinal electronic health record data from preconception to delivery who delivered at Kaiser Permanente Northern California between March 1, 2020, and March 16, 2021. Individuals with diagnostic codes for COVID-19 that did not have a confirmatory polymerase chain reaction test for SARS-CoV-2 were excluded.

EXPOSURES: SARS-CoV-2 infection detected by polymerase chain reaction test (from 30 days before conception to 7 days after delivery) as a time varying exposure.

MAIN OUTCOMES AND MEASURES: Severe maternal morbidity including 21 conditions (eg, acute myocardial infarction, acute renal failure, acute respiratory distress syndrome, and sepsis) that occurred at any time during pregnancy or delivery; preterm birth; pregnancy hypertensive disorders; gestational diabetes; venous thromboembolism (VTE); stillbirth; cesarean delivery; and newborn birth weight and respiratory conditions. Standardized mean differences between individuals with and without SARS-CoV-2 were calculated. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) and 95% CIs for the association between SARS-CoV-2 infection and perinatal complications and hospitalization and to consider the timing of SARS-CoV-2 infection relative to outcomes.

RESULTS: In this study of 43 886 pregnant individuals (mean [SD] age, 30.7 [5.2] years), individuals with a SARS-CoV-2 infection (1332 [3.0%]) were more likely to be younger, Hispanic, multiparous individuals with a higher neighborhood deprivation index and obesity or chronic hypertension. After adjusting for demographic characteristics, comorbidities, and smoking status, individuals with SARS-CoV-2 infection had higher risk for severe maternal morbidity (HR, 2.45; 95% CI, 1.91-3.13), preterm birth (<37 weeks; HR, 2.08; 95% CI, 1.75-2.47), and VTE (HR, 3.08; 95% CI, 1.09-8.74) than individuals without SARS-CoV-2. SARS-CoV-2 infection was also associated with increased risk of medically indicated preterm birth (HR, 2.56; 95% CI, 2.06-3.19); spontaneous preterm birth (HR, 1.61; 95% CI, 1.22-2.13); and early (HR, 2.52; 95% CI, 1.49-4.24), moderate (HR, 2.18; 95% CI, 1.25-3.80), and late (HR, 1.95; 95% CI, 1.61-2.37) preterm birth. Among individuals with SARS-CoV-2 infection, 76 (5.7%) had a hospitalization; pregestational diabetes (HR, 7.03; 95% CI, 2.22-22.2) and Asian or Pacific Islander (HR, 2.33; 95% CI, 1.06-5.11) and Black (HR, 3.14; 95% CI, 1.24-7.93) race and ethnicity were associated with an increased risk of hospitalization.

CONCLUSIONS AND RELEVANCE: In this cohort study, SARS-CoV-2 infection was associated with increased risk of severe maternal morbidity, preterm birth, and VTE. The study findings inform clinicians and patients about the risk of perinatal complications associated with SARS-CoV-2 infection in pregnancy and support vaccination of pregnant individuals and those planning conception.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Ferrara A, Hedderson MM, Zhu Y, et al. Perinatal Complications in Individuals in California With or Without SARS-CoV-2 Infection During Pregnancy. JAMA Intern Med. 2022. PMID: 35311909. doi:10.1001/jamainternmed.2022.0330

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。